Robert Ross
President at SURFACE ONCOLOGY, INC.
Net worth: - $ as of 2024-05-30
Profile
Robert W.
Ross is an Independent Director at Xilio Therapeutics, Inc. since 2022.
He is also a Director at Obsidian Therapeutics, Inc. since 2020.
Prior to his current positions, he served as the President of Surface Oncology, Inc. from 2016 to present.
Before that, he was the Senior Vice President-Clinical Development at bluebird bio, Inc. from 2015 to 2016.
Dr. Ross completed his undergraduate studies at Stanford University and pursued graduate degrees at Harvard Medical School and Columbia University College of Physicians & Surgeons.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
XILIO THERAPEUTICS INC
-.--% | 2024-06-13 | 0 ( -.--% ) | - $ | 2024-05-30 |
Robert Ross active positions
Companies | Position | Start |
---|---|---|
SURFACE ONCOLOGY, INC. | President | - |
XILIO THERAPEUTICS, INC. | Director/Board Member | 2022-06-15 |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Director/Board Member | 2020-09-02 |
Former positions of Robert Ross
Companies | Position | End |
---|---|---|
BLUEBIRD BIO, INC. | Corporate Officer/Principal | 2016-09-30 |
Training of Robert Ross
Stanford University | Undergraduate Degree |
Harvard Medical School | Graduate Degree |
Columbia University College of Physicians & Surgeons | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
BLUEBIRD BIO, INC. | Health Technology |
XILIO THERAPEUTICS, INC. | Health Technology |
Private companies | 2 |
---|---|
Surface Oncology, Inc.
Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Robert Ross